Aman's Global Market Intelligence

Executive dashboard

1 — Index calm hides a rate shock

The S&P and Nasdaq edged higher Friday, but the Dow and Russell fell and the official 10-year Treasury yield crossed 5% to 5.01%; the 2-year rose 9 bp to 4.76%. The equity tape therefore reads as narrow resilience, not clean risk-on confirmation. CNN Markets · U.S. Treasury

2 — Leadership split across regions

Asia finished strong—Nikkei +1.38%, KOSPI +2.66%, Taiwan +1.93%—while Europe sold off, led by DAX −1.60% and FTSE 100 −1.45%. In the U.S., semis recovered but small caps weakened. Friday's cross-market message is selective growth appetite under tightening financial conditions. Yahoo Markets

3 — Next week is policy/data heavy

Scheduled risk clusters around the Sept. 24 U.S.–China summit, Sept. 24 BEA international accounts, Sept. 25 durable goods/sentiment, Sept. 29 JOLTS, and Sept. 30 GDP/PCE, Micron earnings and EASD metabolic data. Weekend prices are unavailable; any crypto or CFD indication should be treated cautiously. BEA · BLS

Asset	Friday level	Friday move	Weekly read*	Interpretation
S&P 500	7,650.50	+0.17%	−0.08%	Flat week despite large intraday regime swings.
Nasdaq Composite	26,522.54	+0.39%	+0.72%	Mega-cap growth resilience.
Dow / Russell 2000	51,682.64 / 2,860.40	−0.18% / −0.50%	−1.69% / −1.50%	Breadth/cyclicals lag.
VIX	14.81	−4.08%	−6.50%	Low implied fear conflicts with macro risk.
U.S. 2Y / 10Y	4.76% / 5.01%	+9 / +7 bp	official close	Restrictive discount rate; 10Y above 5%.
Dollar index	100.22	flat	+1.11%	Weekly tightening impulse for global risk.
WTI / Gold	$100.30 / $4,424.90	−1.58% / +0.57%	+0.25% / +0.36%	Oil remains inflationary; gold still bid.
Nikkei / KOSPI / Taiwan	65,018.95 / 6,894.23 / 47,180.75	+1.38% / +2.66% / +1.93%	+1.57% / −0.23% / +2.16%	Friday tech-led Asia strength.
Hang Seng / Shanghai	24,750.78 / 3,911.87	+0.60% / +0.94%	−0.22% / +0.61%	Modest China improvement ahead of summit.
Euro Stoxx 50 / DAX / FTSE	6,236.20 / 25,304.06 / 10,659.10	−1.37% / −1.60% / −1.45%	−1.41% / −1.03% / +0.08%	Europe rejected Thursday's relief.

*Weekly return is measured from the prior Friday close (Sept. 11) to Sept. 18 using Yahoo chart data; it is not a Monday-open return. Prices are Friday cash/futures settlements, retrieved 08:31–08:35 CEST Saturday and cross-checked against MarketWatch's Friday recap and CNN. No Saturday U.S. equity futures session exists.

Market drivers & coming-week map

Macro, central banks, geopolitics

Fed aftermath: the Sept. 16 FOMC raised the target to 3.75%–4.00%; Friday's curve selloff shows the market still prices inflation/term-premium risk. Fed statement
BOJ: Friday's 25 bp increase to 1.25% did not stop Japanese equities rising, but yen and global-duration sensitivity remain key. BOJ decision
Oil/geopolitics: WTI settled near $100 after easing Friday. A renewed Middle East supply shock is the fastest route to higher yields and lower multiples.
U.S.–China: the Sept. 24 Trump–Xi summit raises tariff, export-control, semiconductor and yuan headline risk. CSIS summit tracker

Data, earnings, rotation

Sept. 24: BEA international transactions/investment position at 08:30 ET; summit policy headlines may dominate markets.
Sept. 25: durable goods and final Michigan sentiment/inflation expectations are the higher-frequency macro checks; verify release times before trading.
Sept. 29–30: JOLTS, then final Q2 GDP and August personal income/PCE at 08:30 ET. At 08:30 Italy, this report will precede every U.S. 08:30 ET release by six hours. BEA schedule · BLS
Sept. 30 after close: Micron's fiscal Q4 call is a direct read-through for HBM/memory pricing and AI supply. Micron IR

Theme dashboards

AI / semis / cloud / power

Selective strength

Friday leaders: VRT +3.27%, AVGO +2.97%, AMD +2.70%, NVDA +1.34%; SMH +2.21% by close-to-close calculation.
Weekly: AMD +8.46% and NVDA +1.82%; VRT −2.98%, AVGO −1.21%, CRWV −8.57%. The rebound is uneven.
Evidence: Broadcom's Sept. 10 10-Q is the primary source for current financials; NVIDIA's latest quarter showed $96.2bn revenue and $108bn Q3 guidance. AVGO 10-Q · NVDA 10-Q
Risk: 5.01% 10Y, AI ROI, debt-funded capex, memory/power constraints, customers, exports and rich expectations.

Quantum & suppliers

Extreme speculation

Friday: IONQ −3.00%, QBTS −3.28%, RGTI −1.44%, while QUBT +3.08%. Weekly gains of 1.85%–8.89% did not translate into Friday breadth.
IonQ: hybrid workflows cut tested engineering-model runtime 5.9%–14.6%, with physical validation on 36-qubit Forte. This is research evidence—not recurring-revenue evidence. IonQ primary release
Government support: Rigetti and D-Wave each finalized up-to-$100m Commerce agreements; milestones, appropriations and government equity/dilution matter. Rigetti · D-Wave
Risk: pre-profit economics, dilution, roadmaps, low commercial visibility and violent squeezes.

Peptide / metabolic biotech

Catalyst-rich / binary

Friday/weekly: LLY +0.04% / +3.34%; NVO +0.12% / +0.39%; VKTX −1.26% / −9.35%; GPCR −0.28% / −9.47%. Small clinical names lagged.
Lilly Phase 3: TRIUMPH-2 reported up to 20.8% average weight loss and 1.6-point A1C reduction at 80 weeks; full statistics/safety arrive Sept. 30. Retatrutide remains investigational. Lilly IR
Registry context: separate Phase 3 retatrutide maintenance and outcomes studies remain active; endpoints include Week-116 body-weight change and long-duration CV/renal composites. ClinicalTrials.gov API
Risk: GI/neuro safety, discontinuations, endpoint hierarchy, reimbursement, manufacturing, competition, cash burn and dilution.

Saturday audit — prior calls, no hindsight edits

Audit compares the rules published at the time with later closes. It does not assume intraday fills, borrow, stop execution or knowledge unavailable then. “Avoid” is not counted as a short return.

Published call	Original rule	What happened	Audit judgment
ORCL bearish/avoid Sept. 14–16	Break $149.84, then $141; later failed reclaim or sub-$139.	Closed $144.79 Monday and $140.35 Tuesday, validating the first two warnings; never closed below $139, rebounded to $150.59 Thursday, ended $147.61.	Mixed / disciplined Initial breakdown worked; later chase was explicitly withheld. Not an open structural short.
VRT avoid Sept. 15–16	Failed rebound and sub-$234 confirmation; invalidate above $250/$261.	Closed $234.61 Tuesday but rebounded; ended $249.39, +3.27% Friday yet −2.98% vs prior Friday.	Mixed Avoid reduced early downside exposure; no clean confirmed short should be claimed.
COHR avoid, do not chase Sept. 15	Only failed $280–290 and renewed sub-$265 break.	Never supplied a closing sub-$265 confirmation; rallied to $317.36 Friday and +3.93% vs prior Friday.	Rule protected Bear trigger did not occur; “do not chase” was essential.
NVDA bullish repair Sept. 15–18	Hold ~$207–211, reclaim ~$219, stronger above $224.	Held support, closed $219.34 Thursday and $222.27 Friday; first trigger met, $224 close not met.	Partially confirmed Upgrade only to conditional long, not full breakout.
LLY bullish Sept. 17–18	Long-term accumulation; EASD is evidence catalyst, not pre-data trade.	Ended $1,152.93, +3.34% vs prior Friday; still below $1,175–1,180 confirmation.	Open / unconfirmed No victory claimed before the clinical presentation.
CRWV avoid Sept. 18	Avoid below $83.35; bear invalidated above $84 with relative strength.	Rebounded 1.85% Friday to $81.36, still below $83.35 and −8.57% vs prior Friday.	Avoid intact One-day bounce did not repair the weekly damage.
QUBT avoid Sept. 17–18	No compelling long; reassess on sustained $8.50–9.00 plus commercial proof.	Closed $8.70 Friday, +3.08%, and +8.89% vs prior Friday; only one close above $8.50 and no verified commercial inflection.	Price challenged; thesis open Avoid lagged the tape; evidence requirement remains unmet.

Ranked ideas — conditional, paper-tracked

Saturday mode: no cash/futures entry is executable. Scores are comparative research judgments, not probabilities. Confidence measures evidence quality. Risk is higher when riskier.

#1 Bullish — NVIDIA (NVDA)

Conditional long

NASDAQ · Mega-cap · Medium/high risk · Horizon: 1–4 weeks and 3–12+ months

Thesis/catalyst: the first repair trigger held at $222.27; Friday's +1.34% and positive weekly return show relative resilience. Fundamental backing is the latest $96.2bn quarter and $108bn Q3 guide. Counterargument: the 10Y at 5.01%, China/export limits, customer concentration and AI-capex funding can compress the multiple.

Entry / confirmationWait for Monday cash price discovery. Swing confirmation: hold $219–220, then close above $224 with SMH breadth. Long-term entries staged, not all-at-once.

Invalidation / downsideClose below ~$213 weakens repair; sustained loss of $207 invalidates. Gaps can exceed research levels.

Evidence$222.27 Friday; +1.34% day, +1.82% prior-Friday-to-Friday. Price history · 10-Q

Key risksRates, exports, supply/memory/power, regulation, competition, customers and AI ROI.

Confidence 84

Risk 64

Opportunity 77

#2 Bullish — Eli Lilly (LLY)

Evidence-gated accumulate

NYSE · Mega-cap pharma · Medium risk · Horizon: 3–12+ months

Thesis/catalyst: commercial incretin scale plus Phase 3 retatrutide and Phase 2 eloraTZP details on Sept. 30. TRIUMPH-2 top line is strong, but full estimand, discontinuation, GI, dysesthesia and safety tables control the upgrade. Counterargument: substantial success is priced in and competition/reimbursement can erode returns.

Entry / confirmationPrefer staged exposure after a hold above $1,175–1,180 or after complete EASD data support efficacy/tolerability. Pullback support zone: ~$1,100.

Invalidation / downsideSustained loss of $1,065, material safety/discontinuation concern, or weaker-than-expected benefit-risk. Clinical gaps bypass stops.

Clinical evidenceTRIUMPH-2: up to 20.8% average weight loss and 1.6-point A1C reduction at 80 weeks; investigational, not approved. Primary source

Key risksSafety, regulation, access/pricing, manufacturing, rivals, litigation and valuation.

Confidence 82

Risk 58

Opportunity 73

#1 Bearish / avoid — CoreWeave (CRWV)

Avoid; no short assumed

NASDAQ · Large-cap/high-beta AI infrastructure · Very high risk · Horizon: day trade and 1–4 weeks

Thesis: a +1.85% Friday bounce left shares at $81.36, below the prior $83.35 reference and down 8.57% versus the previous Friday while Nasdaq rose. Capital intensity, customer concentration and 5% long rates remain adverse. Counterargument: contracts, financing or AI-demand news can cause violent rebounds.

Entry / confirmationAvoid new longs below $83.35. Bearish traders require a failed $83–84 reclaim and renewed break below $79.88; do not chase a gap. Borrow/fees unknown.

Invalidation / downsideHigh-volume close above $84 plus relative strength versus Nasdaq. Short losses can be unlimited.

Evidence$81.36 Friday; +1.85% day but −8.57% prior-Friday-to-Friday. Price history

Key risksHeadline gaps, contracts, leverage/financing, customers/suppliers, power, construction and squeeze.

Confidence 68

Risk 89

Opportunity 60

#2 Avoid — Viking Therapeutics (VKTX)

Small-cap clinical biotech

NASDAQ · Small-cap/pre-revenue · Extreme binary risk · Horizon: 1–4 weeks; evidence-gated 3–12+ months

Thesis: Friday's $28.99 close is −9.35% versus the prior Friday and below the earlier risk controls. Q3 maintenance data remain undated; avoid pre-data positioning without tolerance for a binary gap. Counterargument: Phase 3 VANQUISH trials are enrolled, June cash/investments were ~$502m, and positive durability/safety can sharply rerate shares.

Entry / confirmationNo short suggested. Requalify long only after full maintenance methods, all arms, discontinuations and acceptable safety, plus a close above ~$33–35.

Invalidation / downsideAvoid stance invalidated by strong data and sustained >$35. Long downside includes severe clinical gap or dilution.

Clinical stateMaintenance study ~180 adults; safety/tolerability/PK objectives, exploratory weight durability. Phase 3 subcutaneous programs last 78 weeks. Viking IR

Key risksEndpoints/statistics, GI/safety, Phase 3 spend, runway, FDA path, manufacturing, competition, dilution.

Confidence 76

Risk 94

Opportunity 52

Watchlist — no actionable weekend entry

Rank / ticker	Classification & horizon	Evidence / confirmation	Invalidation & key risk	C / R / O
1 AMD NASDAQ, mega-cap, high beta	Bullish watch Day / 1–4 weeks	$559.82, +2.70% Friday and +8.46% vs prior Friday. Require hold above $545–550 and semiconductor breadth; no gap chase. History	Close below ~$521 breaks momentum; valuation, software execution, exports and capex risk.	73 / 77 / 74
2 VRT NYSE, large-cap AI power/cooling	Reversal watch 1–4 weeks / 3–12 months	$249.39, +3.27% Friday but −2.98% weekly. Require close above $250 then $259 with volume; structural power scarcity remains.	Loss of $240/234; rates, multiple, order conversion and acquisition execution. Vertiv IR	72 / 75 / 69
3 IONQ NYSE, speculative quantum	Research-to-revenue watch 1–4 weeks / 3–12+ months	$39.13, −3.00% Friday but +6.48% weekly. Require sustained >$40 and evidence that 5.9%–14.6% research gains convert to orders/revenue.	Close below ~$36.8; burn, acquired-business mix, dilution, technical roadmap and valuation. IR	73 / 92 / 64
4 NVO NYSE ADR, large-cap pharma	EASD watch 1–4 weeks / 3–12+ months	$43.24; Friday/weekly roughly flat. Sept. 28–Oct. 2 includes oral Wegovy and next-generation amylin evidence. Novo releases	Close below $42.7; efficacy/tolerability, pricing, FX, competition, patents and restructuring.	70 / 73 / 63
5 MU NASDAQ, mega-cap memory	Earnings watch 1–4 weeks	$1,015.80, +4.16% vs prior Friday; Sept. 30 earnings are a direct AI-memory/HBM check. Do not anticipate a binary report. Micron IR	Failed breakout/earnings gap; memory cyclicality, capex, customer concentration, supply and expectations.	75 / 82 / 70

Changes versus the 2026-09-18 report

Regime downgraded: neutral → selective risk-on becomes neutral/risk-high. Friday's modest equity gains were offset by 5.01% 10Y, 4.76% 2Y, $100 oil and weak Dow/Russell breadth.
NVDA remains bullish #1 but not fully confirmed: $222.27 held the first $219–220 trigger; the stronger $224 closing condition remains unmet.
LLY remains bullish #2: no pre-EASD confidence upgrade despite positive weekly performance.
CRWV avoid remains: Friday rebound did not reclaim $83.35 and weekly relative weakness remains severe.
QUBT removed from ranked avoid: its +3.08% Friday and one close above $8.50 challenge the tactical bear case. Commercial proof is still absent, so it is not promoted to bullish.
VKTX added as avoid-until-data/repair: −9.35% weekly and an undated binary readout make pre-data risk/reward unattractive.
AMD and MU enter the top watch ranks: price strength is real, but high rates and Micron's Sept. 30 binary report argue against chasing.

Important 7–30 day catalyst timeline

Sept. 21–25 — Heavy Fed-speaker week after the first hike since 2023; interpret every speech against the official 3.75%–4.00% target and Friday's 5.01% 10Y.

Sept. 23–25 — Quantum World Congress headline window for IONQ/QBTS/RGTI/QUBT. Separate technical demonstrations from contracted revenue and cash economics.

Sept. 24 — Trump–Xi Washington summit; direct export-control, tariff, semiconductor and FX headline risk. Summit background

Sept. 24, 08:30 ET — BEA U.S. international transactions/investment position, Q2. Official schedule

Sept. 25 — U.S. durable goods and final Michigan sentiment/inflation expectations; confirmation with official release calendars is required near event time.

Sept. 28–Oct. 2 — EASD Milan. Lilly presents Phase 3 TRIUMPH-2 retatrutide at 08:30 CEST Sept. 30 and Phase 2 eloraTZP later that day; Novo presents oral Wegovy/amylin evidence. Lilly · Novo

Sept. 29 — August JOLTS at 10:00 ET. BLS schedule

Sept. 30, 08:30 ET — BEA final Q2 GDP and August personal income/PCE; simultaneous releases raise cross-asset gap risk. BEA

Sept. 30 after close — Micron fiscal Q4 financial call; HBM demand, supply, pricing, margins and capex matter across AI semis. Micron

Oct. 2, 08:30 ET — September U.S. employment report; wage/unemployment surprise can reprice the next Fed move. BLS

By quarter-end, company guidance — Viking VK2735 maintenance data. Date is not confirmed; methods, all dose/schedule arms, discontinuations and adverse events control interpretation. Viking IR

Bottom line by horizon

Day trade

Bias: wait for Monday cash price discovery; favor semis only if NVDA/AMD hold Friday breakouts and breadth confirms. Biggest risk: weekend geopolitical/oil gap and renewed Treasury selling. Invalidation: 10Y extends above 5.01% while Nasdaq breadth turns negative.

1–4 week swing

Bias: conditional quality growth over leveraged/speculative beta—NVDA above $219–224; CRWV/VKTX avoided until repair. Biggest risk: summit/PCE/jobs repricing. Invalidation: S&P loses the week's low with VIX expansion and Russell underperformance.

3–12+ month investment

Bias: stage entries in proven platforms and diversified metabolic leaders; keep quantum/clinical biotech as small speculative sleeves. Biggest risk: cash economics fail to justify capex or clinical valuations. Invalidation: estimate cuts, financing stress, adverse benefit-risk data or regulatory restriction.

Data quality & methodology

Quality controls

Primary sources: U.S. Treasury, Federal Reserve, BEA, BLS, BOJ, SEC filings, company IR, ClinicalTrials.gov.
Cross-checks: Yahoo chart API, CNN, MarketWatch and Schwab market reports.
Retrieval: more than five meaningful live retrievals covered market data, current news, macro schedules, filings, trials and company releases.
Saturday convention: no executable equity-futures signal is claimed; all levels are Friday closes/settlements.

Known limitations

Quotes are delayed/non-exchange-direct; Yahoo API and CNN agreed on major closes within normal rounding.
Several company index pages returned 404s and the web extractor rate-limited later requests; direct SEC endpoints, company-release URLs and search-indexed primary pages were used instead.
ClinicalTrials.gov's HTML page returned 403, but its official API succeeded and supplied protocol status/endpoints.
The FDA calendar is secondary and product details were not sufficiently primary-confirmed; no FDA event is promoted into a trade idea. No order book, options surface, analyst-consensus database or borrow/fee data is assumed.

Aman's Global Market Intelligence — 2026-09-19